Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Bourgault, S.; Vaudry, D.; Botia, B.; Couvineau, A.; Laburthe, M.; Vaudry, H.; Fournier, A.
    Novel stable PACAP analogs with potent activity towards the PAC1 receptor (2008), Peptides, 29, 919-932.
    View publication on PubMed

Application

EC Number Application Comment Organism
3.4.14.5 medicine pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide with promising therapeutic applications for the treatment of several pathophysiological states related to neurodegenerative diseases. However, its use for therapeutic applications is actually limited by its restricted bioavailability and rapid degradation. N-terminal modifications confer resistance to dipeptidyl peptidase IV, a major proteolytic process involved in PACAP degradation Sus scrofa

Organism

EC Number Organism UniProt Comment Textmining
3.4.14.5 Sus scrofa
-
-
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
3.4.14.5 kidney
-
 Sus scrofa
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
3.4.14.5 pituitary adenylate cyclase-activating polypeptide + H2O pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide with promising therapeutic applications for the treatment of several pathophysiological states related to neurodegenerative diseases. However, its use for therapeutic applications is actually limited by its restricted bioavailability and rapid degradation. N-terminal modifications confer resistance to dipeptidyl peptidase IV, a major proteolytic process involved in PACAP degradation Sus scrofa ?
-
 ?